1. Home
  2. LZM vs BCYC Comparison

LZM vs BCYC Comparison

Compare LZM & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lifezone Metals Limited

LZM

Lifezone Metals Limited

N/A

Current Price

$4.08

Market Cap

385.4M

ML Signal

N/A

Logo Bicycle Therapeutics plc

BCYC

Bicycle Therapeutics plc

N/A

Current Price

$5.30

Market Cap

456.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
LZM
BCYC
Founded
2021
2009
Country
Isle of Man
United Kingdom
Employees
142
N/A
Industry
Metal Mining
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
385.4M
456.4M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
LZM
BCYC
Price
$4.08
$5.30
Analyst Decision
Strong Buy
Buy
Analyst Count
1
9
Target Price
$7.00
$17.56
AVG Volume (30 Days)
193.6K
309.0K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
42.91
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$510.94
N/A
Revenue Next Year
$217.65
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.90
$5.03
52 Week High
$6.23
$10.84

Technical Indicators

Market Signals
Indicator
LZM
BCYC
Relative Strength Index (RSI) 37.70 39.78
Support Level $3.71 $5.03
Resistance Level $4.42 $5.90
Average True Range (ATR) 0.25 0.28
MACD -0.00 0.02
Stochastic Oscillator 8.00 23.53

Price Performance

Historical Comparison
LZM
BCYC

About LZM Lifezone Metals Limited

Lifezone Metals Ltd seeks to support the clean energy transition through the licensing of Hydromet Technology as an alternative to smelting and metals refining and to become an emerging supplier of responsibly sourced, lower-carbon and lower-sulfur dioxide emission metals to the battery, EV, and hydrogen markets modern pre-development exploration-stage metals company. Its business comprises three segments: Metals extraction and refining for developing and operating a vertically integrated base metal operation in the northwest region of Tanzania and Intellectual property licensing comprises patents residing with and managed by the subsidiary and corporate.

About BCYC Bicycle Therapeutics plc

Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.

Share on Social Networks: